8-K: SI-BONE Reports Strong Q3 2024 Results, Nears Profitability

SI-BONE, Inc. announced a strong third quarter with significant revenue growth and a substantial improvement in adjusted EBITDA, expecting to achieve profitability in the fourth quarter of 2024.

Summary

• SI-BONE, Inc. reported its financial results for the third quarter of 2024, showing a worldwide revenue of $40.3 million, a 19% increase compared to the same period last year.
• U.S. revenue reached $38.3 million, reflecting an 18% growth year-over-year.
• The company's gross margin remained steady at approximately 79%.
• Net loss improved by 34% to $6.6 million, or $0.16 per diluted share.
• Adjusted EBITDA loss significantly improved by 94% to $0.2 million.
• SI-BONE ended the quarter with $150.8 million in cash and equivalents.
• The company has updated its 2024 worldwide revenue guidance to be between $165 million and $166 million, implying a 19% to 20% annual growth.
• SI-BONE expects to achieve positive Adjusted EBITDA in the fourth quarter of 2024.

Sentiment

Score: 8

Explanation: The document conveys a strong positive sentiment due to significant revenue growth, substantial improvement in profitability metrics, and a clear path to achieving positive adjusted EBITDA. The company's strategic initiatives and product launches are also viewed favorably.

Positives

• SI-BONE experienced strong revenue growth both worldwide and in the U.S.
• The company significantly reduced its net loss and adjusted EBITDA loss.
• The company is on track to achieve positive adjusted EBITDA in the fourth quarter of 2024.
• The number of active physicians using SI-BONE products increased by 15%.
• The company successfully refinanced its term loan, improving its financial position.
• SI-BONE received Transitional Pass-Through payment status for CY2025 procedures using Granite.
• The company completed enrollment for the STACI study.

Negatives

• The company still reported a net loss of $6.6 million for the quarter.
• Operating expenses increased by approximately 4% to $39.5 million.
• The company experienced a slight decrease in cash and cash equivalents by $0.7 million.

Risks

• The company's ability to introduce and commercialize new products and indications could impact future performance.
• Recent hurricanes and resulting shortages in operating supplies could affect elective procedure volumes.
• Maintaining favorable reimbursement for procedures using SI-BONE products is crucial.
• Economic weakness could impact patients' ability and desire to undergo elective procedures.
• Supply chain risks and future capital requirements for new surgical systems could pose challenges.
• The pace of healthcare operating environment normalization could affect procedure volumes.

Future Outlook

SI-BONE expects to achieve positive Adjusted EBITDA in the fourth quarter of 2024 and anticipates strong and profitable revenue growth in 2025, leveraging its physician base and new products.

Management Comments

• The team did a tremendous job delivering record worldwide revenue and getting close to Adjusted EBITDA breakeven in the third quarter.
• The record 1,200 active physicians in the quarter demonstrates that our strategy to build anatomy specific platforms to address unmet needs is gaining momentum.
• Given the robust demand trends, including the excitement around Granite 9.5 and TORQ TNT, we are positioned to deliver a strong end to the year and be Adjusted EBITDA profitable in the fourth quarter.
• Going into 2025, we will leverage our formidable physician user base, our breakthrough devices, and our asset-lite business model to deliver strong and profitable revenue growth.

Industry Context

This announcement reflects a positive trend in the medical device industry, where companies are focusing on innovative solutions and achieving profitability through strategic growth and cost management. SI-BONE's focus on sacropelvic disorders and minimally invasive procedures aligns with current market demands.

Comparison to Industry Standards

• SI-BONE's 19% revenue growth is strong compared to the broader medical device industry, which often sees single-digit growth rates.
• Companies like Globus Medical and NuVasive, which also focus on spinal and orthopedic solutions, have reported varying growth rates, but SI-BONE's focus on a specific niche (sacropelvic disorders) may give it a competitive edge.
• The improvement in Adjusted EBITDA is a positive sign, as many medical device companies struggle with profitability in their early stages. SI-BONE's move towards profitability is a key differentiator.
• The company's gross margin of 79% is generally high for the medical device industry, indicating efficient cost management.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and the prospect of profitability.
• Employees may benefit from the company's growth and improved financial stability.
• Customers (physicians and patients) will have access to innovative solutions for sacropelvic disorders.
• Suppliers may see increased demand for their products and services.
• Creditors will likely view the company's improved financial position favorably.

Next Steps

• SI-BONE will host a conference call to discuss the third quarter 2024 financial results on November 12, 2024.
• The company will continue to focus on commercializing new products and expanding its physician user base.
• SI-BONE will leverage its assets to achieve strong and profitable revenue growth in 2025.

Key Dates

Keywords

SI-BONE, Sacropelvic Disorders, Medical Devices, iFuse, Adjusted EBITDA, Revenue Growth, Financial Results, Gross Margin, Net Loss, Healthcare, Spinal Fusion, Orthopedics